Ioannis Doundoulakis

Dr. Ioannis Doundoulakis

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Clinical Nutrition
Verified
Journal Article
Closed access
Kalliopi-Anna PouliaKalliopi-Anna Poulia
Kalliopi-Anna Poulia
SKStanislaw Klek
Stanislaw Klek
IDIoannis Doundoulakis
Ioannis Doundoulakis
EBEmmanouil Bouras
Emmanouil Bouras
DKDimitrios Karagiannis
Dimitrios Karagiannis
MCMichael Chourdakis
Michael Chourdakis

18 August 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
AVAndreas Vadarlis
Andreas Vadarlis
CAChristina Antza
Christina Antza
DBDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
IDIoannis Doundoulakis
Ioannis Doundoulakis
GKGeorgios Kalopitas
Georgios Kalopitas
MCMichael Chourdakis
Michael Chourdakis

28 January 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SSStergios Soulaidopoulos
Stergios Soulaidopoulos
ATAikaterini Tsiogka
Aikaterini Tsiogka
CCChristina Chrysohoou
Christina Chrysohoou
ELEmilia Lazarou
Emilia Lazarou
Konstantinos AznaouridisKonstantinos Aznaouridis
Konstantinos Aznaouridis
George LazarosGeorge Lazaros
George Lazaros
Despite the remarkable development of the medical industry in the current era, herbal products with therapeutic potentials arise as attractive alternative treatments. Consequently, Chios mastiha, a natural, aromatic resin obtained from the trunk and brunches of the mastic tree, has recently gained increasing scientific interest due to its multiple beneficial actions. Chios mastiha is being exclusively produced on the southern part of Chios, a Greek island situated in the northern Aegean Sea, and its therapeutic properties have been known since Greek antiquity. There is now substantial evidence to suggest that mastiha demonstrates a plethora of favorable effects, mainly attributed to the anti-inflammatory and anti-oxidative properties of its components. The main use of mastiha nowadays, however, is for the production of natural chewing gum, although an approval by the European Medicines Agency for mild dyspeptic disorders and for inflammations of the skin has been given. The aim of this article is to summarize the most important data about the therapeutic actions of Chios mastiha and discuss future fields for its medical application.

30 August 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
SZStefanos Zafeiropoulos
Stefanos Zafeiropoulos
IFIoannis Farmakis
Ioannis Farmakis
IMIoannis Milioglou
Ioannis Milioglou
IDIoannis Doundoulakis
Ioannis Doundoulakis
EGEiran Z. Gorodeski
Eiran Z. Gorodeski
George GiannakoulasGeorge Giannakoulas
George Giannakoulas

1 January 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
Roberto MenèRoberto Menè
Roberto Menè
SBSerge Boveda
Serge Boveda
DRDomenico Giovanni. Della Rocca
Domenico Giovanni. Della Rocca
VSVasileios Sousonis
Vasileios Sousonis
GVGiampaolo Vetta
Giampaolo Vetta
SCStéphane Combes
Stéphane Combes

23 November 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
GVGiampaolo Vetta
Giampaolo Vetta
DRDomenico Giovanni. Della Rocca
Domenico Giovanni. Della Rocca
APAntonio Parlavecchio
Antonio Parlavecchio
MMMichele Magnocavallo
Michele Magnocavallo
ASAntonio Sorgente
Antonio Sorgente
GCGian Battista Chierchia
Gian Battista Chierchia
Pulsed field ablation (PFA) is an innovative technology recently adopted for the treatment of atrial fibrillation (AF). Preclinical and clinical studies have reported a remarkable safety profile, as a result of its tissue specific effect targeting cardiomyocytes and sparing adjacent tissues. Single-shot pentaspline system was the first PFA device to receive regulatory approval. We performed a meta-analysis to compare the efficacy and safety of PFA with the single-shot pentaspline system versus currently available 2nd/3rd/4th generation Cryoballoon technologies (CRYO). We systematically searched electronic databases for studies focusing on AF ablation employing the PFA single-shot pentaspline system or 2nd/3rd/4th generation CRYO technologies. The primary endpoints were acute procedural success assessed on a vein and patient basis. Safety endpoints included overall periprocedural complications and major periprocedural complications. We also compared procedural, fluoroscopy times, and freedom from atrial tachyarrhythmias (ATs) at follow-up (secondary endpoints). Twenty and 70 studies were included for PFA and CRYO, respectively. PFA demonstrated greater acute procedural success on a vein basis (99.9% vs 99.1%; p<0.001), as well as per patient (99.5% vs 98.4%; p<0.001). PFA yielded lower overall periprocedural complications (3.1% vs 5.6%; p<0.001), shorter procedural time (75.9 min vs 105.6 min; p<0.001) and fluoroscopy time (14.2 min vs 18.9 min; p<0.001) compared to CRYO. No differences were found for major periprocedural complications (1.2% vs 1.0%; p=0.46) and freedom from ATs at 1 year (82.3% vs 80.3%; Log-rank p= 0.61). PFA contributed to higher acute procedural success, and safety compared to CRYO. No statistically significant differences in AT recurrence at 1-year follow-up were observed.